

## Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

### A Clinical Guideline

|   |  |
|---|--|
| <b>For Use in:</b>  | Jenny Lind Children's Department   |
| <b>By:</b>  | Medical and Nursing Staff  |
| <b>For:</b>   | Children (0-16) who are on Azathioprine or being considered for Azathioprine treatment   |
| <b>Division responsible for document:</b>   | Paediatrics  |
| <b>Key words:</b>   | Azathioprine, Immunomodulator agent, Immunosuppression, 6-mercaptopurine   |
| <b>Name and job title of document author's:</b>   | Dr Mary-Anne Morris, Consultant in Paediatric Gastroenterology, EoEPGN member, Dr G Briars Consultant in Paediatric Gastroenterology EoEPGN member           |
| <b>Name and job title of document author's Line Manager:</b>  | Dr Aravind Shastri, Service Director Paediatric Medicine   |
| <b>Supported by:</b>  | EoEPGN Steering Group<br>Rosalind Howe – Clinical Pharmacist   |
| <b>Assessed and approved by the:</b>  | Clinical Guidelines Assessment Panel (CGAP)<br><br>If approved by committee or Governance Lead Chair's Action; tick here <input checked="" type="checkbox"/> |
| <b>Date of approval:</b>  | 17/03/2022   |
| <b>Ratified by or reported as approved to (if applicable):</b>  | Clinical Safety and Effectiveness Sub-board  |
| <b>To be reviewed before:</b><br>This document remains current after this date but will be under review | 17/03/2025   |
| <b>To be reviewed by:</b>   | Dr Mary-Anne Morris/Dr Graham Briars   |
| <b>Reference and / or Trust Docs ID No:</b>   | CA5056 id 8271   |
| <b>Version No:</b>  | 5  |
| <b>Compliance links: (is there any NICE related to guidance)</b>  | None   |

This guideline has been approved by the Trust's Clinical Guidelines Assessment Panel as an aid to the diagnosis and management of relevant patients and clinical circumstances. Not every patient or situation fits neatly into a standard guideline scenario and the guideline must be interpreted and applied in practice in the light of prevailing clinical circumstances, the diagnostic and treatment options available and the professional judgement, knowledge and expertise of relevant clinicians. It is advised that the rationale for any departure from relevant guidance should be documented in the patient's case notes.

The Trust's guidelines are made publicly available as part of the collective endeavour to continuously improve the quality of healthcare through sharing medical experience and knowledge. The Trust accepts no responsibility for any misunderstanding or misapplication of this document.

# Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

## Version and Document Control:

| Version Number | Date of Update | Change Description   | Author                             |
|----------------|----------------|--|------------------------------------|
| 5              | 17/03/2022     | Minor changes following review. Agreed at Paed Gastroenterology team. Updating of section E -Monitoring of metabolites, with input from Rosalind Howe. | Dr Mary-Anne Morris<br>Dr G Briars |
|                |                |  |                                    |
|                |                |  |                                    |
|                |                |  |                                    |

## This is a Controlled Document

Printed copies of this document may not be up to date. Please check the hospital intranet for the latest version and destroy all previous versions.

# Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

## Objective/s

To ensure safe prescribing of azathioprine and effective monitoring of possible side effects in children who are prescribed azathioprine as an Immunomodulator Drug for gastroenterological conditions.

## Rationale

A significant number of children with Inflammatory Bowel Disease and some children with conditions like autoimmune diseases or transplant recipients need an immunosuppressant drug to achieve long term control of inflammation. Azathioprine is the first line immunosuppressant in inflammatory bowel disease. It is usually well tolerated but there are potential side effects and contraindications to its use. Azathioprine is a pro-drug, which is split rapidly in the liver to 6-mercaptopurine and then metabolised to the active metabolite 6-thioguanine. Thiopurine Methyl Transferase (TPMT) is an enzyme involved in the pathway. Testing TPMT activity helps to identify patients at risk of early profound myelosuppression and is recommended prior to treatment. Myelosuppression may still occur in the presence of normal TPMT activity, which also does not identify patients at risk of other toxic or allergic adverse effects, therefore regular monitoring of signs, symptoms and blood results are necessary.

This guideline has been formulated to provide guidance to professionals involved in the prescribing or monitoring of children on azathioprine.

## Broad recommendations

- Decision to start azathioprine in children will be taken by the named Paediatric Consultant working within the EoEPGN after counselling of patient and parents/guardian.
- Patient information leaflet and Blood monitoring schedule should be provided to the patient and parents. (Attached Patient Info Sheet- Appendix 1)
- Thiopurine Methyl Transferase (TPMT) level should be checked and results should preferably be available prior to commencement of azathioprine. This can be checked by sending 5 mL of EDTA blood to Chemical Pathology. The results take 1-2 weeks. Blood transfusion within the last three months may give spurious results.
- The dose prescribed for individual patient is at the discretion of the Consultant prescribing it but will usually be a starting dose of 2.0-2.5mg/kg once a day with normal TPMT levels, 0.5-1mg/kg once a day if TPMT levels are low and it should not be prescribed if TPMT is very low/absent as defined by laboratory standards.
- Clinical response to azathioprine will be assessed in follow up clinics and will be based on clinical symptoms, signs and blood results. Response may take up to 10-14 weeks after the start of treatment.
- Thiopurine metabolites (6TGN, 6MMP) can be measured to guide dosing. This is usually after 8 week treatment or if there is concern about efficacy or compliance
- Blood tests to monitor unwanted side effects of the drug should be carried out as per the Guidelines under the supervision of the Hospital Consultant.

## Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

Request forms for all monitoring bloods will be supplied by the paediatric gastroenterology team. Amylase if not routinely measured but should be done urgently if abdominal pain is reported.

- Patient should be made aware of warning signs and symptoms which they need to report urgently. (Patient Info Sheet)
- Patients of reproductive age group, both male and female, should be advised to avoid pregnancy whilst taking azathioprine and for 3 months after discontinuation. This should be clearly documented.

### Dosage and administration

If patient has normal TPMT status the initial recommended starting dose is **2-2.5 mg/kg once a day** <sup>2,12,13,14</sup> orally *with or after food often tolerated better if taken at night* and can be titrated according to response. (Grade A;Level II evidence). Children with Low TPMT activity should be started at a dose between 0.5-1mg/kg once a day.<sup>212,134</sup> (Grade B;Level III evidence). Levels as defined by laboratory standards. Azathioprine is available as 25mg and 50mg tablets and 50mg in 5ml oral solution (unlicensed Special)

### Contraindications to use of Azathioprine

- 1) Known hypersensitivity to the Drug <sup>2,13</sup>
- 2) Significant haematological impairment
- 3) Moderate to severe renal or hepatic insufficiency (azathioprine may be prescribed specifically for autoimmune liver disease)
- 4) In adolescent girls who may be pregnant or hope to become pregnant in near future. (Azathioprine should not be started without careful assessment of risk versus benefit in such patients)
- 5) Thiopurine induced pancreatitis
- 6) Severe infection
- 7) TPMT deficiency (reduce dose if levels are low)

### Cautions

- 1) Increased risk of haematological toxicity with co-trimoxazole / trimethoprim
- 2) Patients on azathioprine must not have live vaccines such as Oral Polio, Oral Typhoid, MMR, BCG, nasal influenza and Yellow fever. Due to risk of orofaecal transmission other family members should receive Inactive Polio Vaccine if needed.
- 3) Concurrent allopurinol administration (not an absolute contraindication and can be used to manage hypermetabolism: (see section E)– Azathioprine dose to be reduced to quarter of normal)
- 4) Patients should try to avoid any contact with people who have active chicken pox or shingles and should report any such contact to their GP or Hospital Specialist for consideration of Varicella zoster Immunoglobulin.
- 5) Anticoagulant effect of warfarin may be impaired with azathioprine

## Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

- 6) Increased sun-protection to be advised (sun-screen against UVA/UVB) given reports of 4-5 fold increased risk of non-melanoma skin cancers in patients on thiopurines (ref Ulrich)
- 7) Patients on azathioprine are recommended to have injected influenza vaccination annually.

### Red Flag symptoms while on Azathioprine

Patients should report the following warning symptoms immediately to their GP or Hospital Consultant: (Patient info sheet)

- 1) Significant new rash (check FBC for dyscrasia)
- 2) Severe infections, fever , chills
- 3) Sore throat >5 Days
- 4) Moderate to severe upper/central abdominal pain (check amylase)
- 5) Abnormal bruising or bleeding.
- 6) Severe nausea, vomiting or diarrhoea
- 7) Chicken pox rash

### Other Adverse effects

- 1) Nausea, vomiting, diarrhoea, anorexia and dyspepsia (5-8% patients)
- 2) Hepatotoxicity
- 3) Myelosuppression
- 4) Increased risk of infection
- 5) Hypersensitivity reactions
- 6) Rarely pancreatitis (3-4% of patients, usually presents in first 6 weeks of treatment, is independent of dose and is most often a hypersensitivity reaction. It usually requires discontinuation of azathioprine)

### Monitoring of Blood Biochemistry and Haematology Results

**A) Pre-Treatment assessment:** FBC, LFT, TPMT activity<sup>2,13</sup>, Varicella Status <sup>2,10</sup>

**B) Monitoring:** <sup>2,10,12</sup>

|         |  |
|---------|--|
| FBC     | Fortnightly in the 1 <sup>st</sup> and 2 <sup>nd</sup> month then monthly for the next 4/12, then 3 monthly from the 6th month onwards till any dose change. |
| LFT     | As above   |
| CRP/ESR | As clinically indicated to assess disease activity   |
| U&E     | At least once monthly from start, then 3 monthly from 3 <sup>rd</sup> month  |
| Amylase | If there is any complaint of central abdominal pain and/or pancreatitis is suspected   |

## Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

**Consider need for increased monitoring if dose is increased.** A local audit of blood monitoring demonstrated poor compliance with weekly blood tests and no side effects from Azathioprine that would have been detected by weekly testing (Dr Briars, personal communication). The frequency of FBC monitoring is in line with UK best practice and ECCO guideline (14).

### C) Action on abnormal results:

- If any of the following noted urgent Medical review is needed if child is unwell or inform named Consultant if child is well:
- Sore throat with oral or pharyngeal ulceration
- Unexplained bruising /bleeding or appearance of new rash

| Blood test results |                                | Action  |
|--------------------|--------------------------------|---|
| Total WBC          | 2.5 - 4 x 10 <sup>9</sup> /L   | Reduce dose and repeat FBC.   |
|                    | 1.5 - 2.5 x 10 <sup>9</sup> /L | Withhold drug and repeat in 1 week. Consider restarting at lower dose with weekly FBC monitoring. |
|                    | <1.5 x 10 <sup>9</sup> /L      | Withdraw treatment.   |
| Neutrophils        | < 1.0 x 10 <sup>9</sup> /L     | Repeat and discuss with Consultant  |
| Lymphocytes        | < 0.5 x 10 <sup>9</sup> /L     | Repeat and discuss with Consultant if still low   |
| Platelets          | <150 x 10 <sup>9</sup> /L      | Repeat and discuss with Consultant  |
| AST/ALT/ALP        | >2 fold rise                   | Repeat and if still high discuss with named Consultant  |
|                    | >4 fold rise                   | Withhold medication, repeat and discuss with named Consultant                                     |

### D) Exposure to Chicken pox infection or Clinical infection

Follow guidance from Immunisation against infectious disease. (Green Book)

[http://www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/DH\\_4097254](http://www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/DH_4097254)

Immunisation against Varicella should be considered prior to starting immunosuppression in those without protective antibodies.

### E) Monitoring of metabolites

Consider measuring 6TGN and 6MMP in patients with raised liver enzymes, cytopenia or suboptimal response.

## Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

| 6-TGN                    | 6-MMP             | Possible adverse event or finding   | Interpretation                                 | Recommendation   |
|--------------------------|-------------------|-------------------------------------|--|--|
| Low<br>[<230]            | Normal<br>[<5700] | -                                   | Under-dosing or low compliance                 | Increase compliance or thiopurine dose as appropriate  |
| Low<br>[<230]            | High<br>[≥5700]   | Hepatotoxicity and others           | TPMT hyper-metaboliser                         | Consider allopurinol co-treatment and thiopurine dose reduction to 25–33% of standard dose, or change medication |
| Therapeutic<br>[230–450] | Normal or high    | Refractoriness                      | Therapy failure                                | If clinically resistant, change medication   |
| High<br>[>450]           | Normal            | Myelosuppression                    | Low TPMT activity [heterozygote or homozygote] | Change drug category if homozygote, or reduce dose to half if heterozygote                                       |
| High                     | High              | Myelosuppression and hepatotoxicity | Overdosing                                     | Reduce dose and if clinically resistant, change drug category  |

### Clinical audit standards

- Pre-treatment blood tests performed and documented.
- Written information given to patient/family and documented.
- Monitoring of blood tests within guidelines.
- Actions taken on the basis of side effects clearly documented.

### Summary of development and consultation process undertaken before registration and dissemination

This guideline has been drafted based on local and National guidelines that exist for the use of azathioprine in adult patients and recent scientific evidences available for the recommendations. During its development it has been circulated for comment within the NNUH Paediatric Directorate and Pharmacy Department. It was then reviewed by the East of England Paediatric Gastroenterology Network and comments have been incorporated into the final version where appropriate.

The guideline was revised by Dr Briars and Dr Morris in 2015. The patient front sheet for documenting side effects has been superseded by Paradox database and is therefore deleted. The interval for FBC monitoring has been increased from weekly to fortnightly in the first month in line with UK best practise and after an audit had demonstrated poor compliance with weekly bloods and an absence of clinical benefit. Guideline review in 2018 resulted in the addition of reference 14 (BSPGHAN guideline), clarification of starting dose and addition of statements on influenza

## Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

vaccination. Review in 2022 by Dr Morris and Ros Howe revised rationale and added section E.

### Distribution list/ dissemination method

Pharmacy Services  
Trust Intranet

### References/ source documents

- 1) Geary RB & Barclay ML (2005) [Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease](#). J Gastroenterol Hepato, 120, 1149 – 1157.
- 2) British Society of Paediatric Gastroenterology Hepatology and Nutrition Guidelines for the management of IBD in children. 2008. <https://www.bspghan.org.uk/documents/IBDGuidelines.pdf>
- 3) Teml A, Schaeffeler E, Herrlinger KR *et al.* (2007) [Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing](#). Clin Pharmacokinet. 46, 187 – 208.
- 4) Al Hadithy AFY, de Boer NKH, Derijks LJJ, *et al.* (2005) [Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations](#). Dig Liver Dis. 37, 282 – 297.
- 5) [Gisbert JP, González-Lama Y, Maté J. \(2007\). Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review](#). Am J Gastroenterol. 102, 1518 – 1527.
- 6) [Gisbert JP, Gomollón F, Cara C, Luna M, González-Lama Y, Pajares JM, Maté J, Guijarro LG. \(2007\) Thiopurine methyltransferase activity in Spain: a study of 14,545 patients](#). Dig Dis Sci. 52(5), 1262 – 1269.
- 7) Systematic Review of Cochrane Database 2012 Azathioprine and 6-MP for maintenance of remission in Ulcerative Colitis. A.Timmer, JWD McDonald, JK MacDonald
- 8) Systematic Review of Cochrane Database 2009 – Azathioprine and 6-MP for maintenance of remission in Crohn's disease. DC Pearson, GR May, G Fick
- 9) [Gisbert JP, Maté J, Gomollón F, González-Guijarro L, Cara C, Pajares JM. \(2006\) Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase \(TPMT\) activity to avoid myelosuppression. A prospective study](#). Hepato-gastroenterology. 53, 399 – 404.
- 10) Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. (2006) American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators and Infliximab in Inflammatory Bowel Disease. Gastroenterology, 130: 935-939
- 11) Greater Manchester Interface Prescribing group – Shared Care Guidelines for chronic IBD. May 2007
- 12) British National Formulary for Children- 2018  
<https://doi.org/10.18578/BNFC.584089745> Anstey AV, Wakelin S, Reynolds



## Guideline for the Management of Azathioprine Therapy in Children with Gastroenterological Conditions

NJ. (2004) Guidelines for prescribing Azathioprine in Dermatology . British Journal of Dermatology 151, 1123 – 1132.

13) Ruemmele FM, et al, (2014) Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease, J Crohns Colitis 8, 1179 – 1207. <http://dx.doi.org/10.1016/j.crohns.2014.04.005>

14) BSPGHAN IBD working group. Thiopurine Blood Monitoring Guidelines <http://bspghan.org.uk/documents/Azathioprine%20Guidelines%20BSPGHAN%20Final.pdf>

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update 2020 <https://doi.org/10.1093/ecco-jcc/jjaa161>

### Appendix 1:

Information on Azathioprine for Inflammatory Bowel Disease (Paediatrics)  
[Trustdocs Id: 9724](#)